Up Patenting Adverse Events Vaccine Technology Publications Press Releases Press Coverage

Last Updated August 31, 2011   

                    

Classen Immunotherapies Inc.

                              Vaccine Safety First!

emblem02.WMF (637208 bytes)

Dedicated: to understanding the chronic effects of vaccines and developing safer immunization methods for those who choose to be immunized.

 

Committed: to discovering safer uses of vaccines , drugs and chemicals.

 

        Classen Immunotherapies, Inc. is a privately held research stage biopharmaceutical company devoted to discovering safer uses of vaccines, drugs, devices, chemicals and related products. Classen Immunotherapies discovered that common vaccines are one of the most important causes of diabetes in children and in highly immunized adults. Management  believes that many drugs and chemicals also cause severe adverse events that have not yet been discovered. Epidemiology and other tools can be used to identify high risk situations where the use of a drug or other agent should be avoided. Examples of situations where use of a drug should be avoided include situations where serious adverse drug drug interactions are common and situations where serious adverse interactions between drugs and existing medical conditions are common.

        Classen Immunotherapies believes that research to discover adverse events has been severely hampered because there has been little financial incentive to discover adverse events and little incentive for manufacturers to disclose adverse events. As a results many individuals have been unnecessarily injured by drug adverse events and drug adverse events are now one of the largest causes of morbidity and mortality in the United States. Classen Immunotherapies has developed and patented  methods which create financial incentives for finding and disclosing adverse event information. These methods pertain to patenting the disclosure of adverse events. The methods are expected to lower the cost of drugs and other products through lowering the frequency of costly adverse events. While the costs of adverse events are often hidden to consumers, consumers pay for these costs through increased insurance payments. Classen Immunotherapies' patented methods are discussed in one of the following pages (Patenting the disclosure of adverse events)

        John Barthelow Classen, M. D., M. B. A., is President and Chief Executive Officer of Classen Immunotherapies. Besides overseeing development of the company's products, he has acted as a biotechnology consultant advising several New York investment firms. He advised the biotechnology analyst and several investment bankers at Prudential Securities between 1991 and 1994 . Dr. Classen was employed at the National Institutes of Health in the Laboratory of Immunology, NIAID, between 1988 and 1991 before leaving to found Classen Immunotherapies in 1991. He received his M.D. from the University of Maryland in 1988 and his M.B.A. from Columbia University in 1992.

 

Classen Immunotherapies, Inc.

6517 Montrose Avenue,

Baltimore, Maryland   21212         U.S.A.

Contact: classen@vaccines.net

Tel: 410.377.8526